Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

[1]  R. Gabbay,et al.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2022, Diabetologia.

[2]  R. Gabbay,et al.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2022, Diabetologia.

[3]  J. Mariani,et al.  Prescription trends and costs of diabetes medications in Australia between 2003 and 2019: an analysis and review of the literature , 2020, Internal medicine journal.

[4]  Sitagliptin , 2019, Reactions Weekly.

[5]  C. Bailey,et al.  Metformin: historical overview , 2017, Diabetologia.

[6]  J. Holst,et al.  Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and “Isoglycemic” Intravenous Glucose , 2014, Diabetes.

[7]  S. Gough,et al.  Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus , 2013, Clinical medicine insights. Endocrinology and diabetes.

[8]  Shannon A. Miller,et al.  Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus. , 2012, P & T : a peer-reviewed journal for formulary management.

[9]  K. Iglay,et al.  Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis , 2012, Current medical research and opinion.

[10]  J. Piercy,et al.  Fixed-Dose Combination Antidiabetic Therapy: Real-World Factors Associated with Prescribing Choices and Relationship with Patient Satisfaction and Compliance , 2012, Advances in Therapy.

[11]  Claudine M. Chwieduk.  Sitagliptin/Metformin Fixed-Dose Combination , 2011, Drugs.

[12]  R. Fleurence,et al.  A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes , 2011, Current medical research and opinion.

[13]  K. Lyseng-Williamson,et al.  Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. , 2008, PharmacoEconomics.

[14]  J. Chan,et al.  Metformin - The gold standard:a scientific handbook , 2007 .

[15]  W. Zeng,et al.  Dose‐proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers , 2007, Biopharmaceutics & drug disposition.

[16]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON CONDUCT OF PHARMACOVIGILANCE FOR MEDICINES USED BY THE PAEDIATRIC POPULATION , 2007 .

[17]  G. Herman,et al.  Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes , 2006, Current medical research and opinion.

[18]  W. Zeng,et al.  Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. , 2006, Clinical therapeutics.